Showing results (501-510 of 1,963) with videos related to

Sort By:
Pageof 197
RMD Open|December 4, 2021
Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximabCathy Mireille Melong Pianta Taleng, Kim Lauper, Benoit Gilbert, et al.
RMD Open|March 20, 2019
Undifferentiated connective tissue disease: state of the art on clinical practice guidelinesMargarida Antunes, Carlo Alberto Scirè, Rosaria Talarico, et al.
RMD Open|March 20, 2019
Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analysesErnest Choy, Nick Freemantle, Clare Proudfoot, et al.
RMD Open|March 20, 2019
Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
RMD Open|February 23, 2019
Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trialsBénédicte Champs, Yannick Degboé, Thomas Barnetche, et al.
RMD Open|August 16, 2019
Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritisAlexandre Virone, Jean-Philippe Bastard, Soraya Fellahi, et al.
RMD Open|August 16, 2019
Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: results from the METEOR registrySytske Anne Bergstra, Maura C Couto, Nimmisha Govind, et al.
RMD Open|February 2, 2021
Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE)Daniel Aletaha, Clifton O Bingham, George Athanasios Karpouzas, et al.
RMD Open|January 18, 2021
Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?Cristiana Sieiro Santos, Xenia Cásas Férnandez, Clara Moriano Morales, et al.
RMD Open|January 28, 2021
Effect of significant weight loss on disease activity: reason to implement this non-pharmaceutical intervention in daily clinical practiceJulia M Weijers, Wieland D Müskens, Piet L C M van Riel
Pageof 197